Design, synthesis, and biological evaluation of 4‐aminopyrimidine or 4,6‐diaminopyrimidine derivatives as beta amyloid cleaving enzyme‐1 inhibitors

This is the authors' abstract. We don't add key points for this paper.

A series of novel aminopyrimidine and diaminopyrimidine derivatives were designed and optimized to improve their potency and permeability relative to lead compound 1 (IC50 = 37.4 μM), which was discovered in a previous virtual screening. The potency of the optimized compound, 13g (IC50 = 1.4 μM), was 26‐fold greater than that of 1 based on a fluorescence resonance energy transfer assay, and a parallel artificial membrane permeability assay suggested that it could pass through the blood‐brain barrier. Additionally, several compounds containing selenium showed good potencies and deserve further investigation as anti‐Alzheimer's agents.